Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06226883 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
A Phase 2 study of Crohn's Disease and Inflammatory Bowel Diseases, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
- 20
- Study locations
NCT06226883 is a Phase 2 study of Crohn's Disease and Inflammatory Bowel Diseases that is actively recruiting participants, run by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company). The registered enrollment target is 385 participants, below the 2,411-participant average among 104 other Crohn's Disease trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06226883, a Phase 2 study of Crohn's Disease and Inflammatory Bowel Diseases, is actively recruiting participants, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MORF-057
Study Locations (20)
Texas
- GI Alliance - Cedar Park - Cedar Park
- The University of Texas Health Science Center at Houston - Houston
- Texas Digestive Disease Consultants - San Marcos
- Tyler Research Institute, LLC - Tyler
North Carolina
- Cross Creek Medical Clinic - Fayetteville
- Peters Medical Research - High Point
- Wake Research Associates - Raleigh
California
- Gastro Care Institute - Lancaster
- Infinity Clinical Research - San Diego
Florida
- Clinical Research of Osceola - Kissimmee
- Bioresearch Partner-Kendale Lakes - Miami
Georgia
- Atlanta Gastroenterology Specialists, PC - Atlanta
- Atlanta Gastroenterology Associates (Part of United Digestive) - Atlanta
Other
- Medical University Hematology - Innsbruck
- Salzburg Regional Hospital - Salzburg
Colorado
- Peak Gastroenterology Associates - Colorado Springs - Colorado Springs
South Carolina
- Palmetto Gastroenterology Clinical Research - Summerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2024-07-18 |
| Est. Completion | 2030-06 |
| Phase | Phase 2 |
Sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)4 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06226883
The ClinicalTrials.gov registry entry for NCT06226883 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,411-participant average among 104 other Crohn's Disease trials with a reported enrollment target (84% lower). The listed sponsor is Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company), which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06226883 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Texas, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT06226883 about?
NCT06226883 is a clinical study titled "A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease". This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
What is the current status of trial NCT06226883?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2024-07-18. Estimated completion is 2030-06.
What conditions does trial NCT06226883 study?
This clinical trial studies the following conditions: Crohn's Disease, Inflammatory Bowel Diseases.
What interventions are being tested in trial NCT06226883?
The interventions under investigation include: Placebo (DRUG), MORF-057 (DRUG).
Who is sponsoring clinical trial NCT06226883?
This trial is sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company), which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06226883 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
RECRUITING · Phase 2
-
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.